Billede
FluoGuide
Sundhed - Medicinske Instrumenter og materialer

FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs.

The Company has demonstrated efficacy of FG001 as well as it being well tolerated and safe in the completed proof-of-concept clinical study (phase I/IIa) in patients with high grade glioma undergoing surgery. A phase IIb trial in aggressive brain cancer is ongoing to obtain valuable information to design the phase III trial.  In addition, FluoGuide currently explores FG001 lung and head & neck cancer, and a trail in in meningioma and low grade glioma is commencing. FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker “FLUO”.

An introduction to FluoGuide:

Bliv medlem for kun 795,- årligt

Du får:

Svarende til 66 kr./md.

Ubegrænset adgang - og meget mere.

  • Aktietips & artikler
  • Ugentlige nyhedsbreve
  • 9 magasiner af Aktionæren
  • Danmarks største rabatportal
  • Analyser
  • Aktie-TV & videoer 
  • Arrangementer & events
  • Masterclasses
  • Guides
  • Lokalforeningsnetværk
  • Investorredskaber
  • Digital uddannelse & kurser
  • Konkurrencer
  • InvestorSparring
  • Adgang til InvestorUgen
  • Støtter aktionærdemokratiet

Ingen binding, kan altid opsiges til udløb af kontingentperiode.

Du får også tilsendt seneste nummer af magasinet Aktionæren ved indmeldelse (værdi 79,95).

Medlemskabet fornyes årligt - priserne er inkl. moms.

Bliv medlem Icon
Aktie-TV

Knæk Cancer: Kræftforskning i fokus

Et dansk selskab slår dem alle i størrelse, når det handler om kræftforskning. Men sådan har det ikke altid været. Se vores to tema-udsendelser i anledning af Knæk Cancer-ugen, og få et indblik i de mange selskaber, der ...
27. oktober 2023